ea0038p146 | Neoplasia, cancer and late effects | SFEBES2015
Stevenson Mark
, Walls Gerard
, Soukup Ben
, Lines Kate
, Grossman Ashley
, Schmid Herbert
, Thakker Rajesh
Improved therapies for pancreatic and pituitary neuroendocrine tumors (NETs), which may occur in Multiple Endocrine Neoplasia type 1 (MEN1), are needed. We assessed the effects of pasireotide, a somatostatin analogue with high affinity for somatostatin receptors (SSTRs) −1, −2, −3 and −5, in a mouse model of MEN1. Men1+/− mice treated from 12 months of age with 40 μg/g pasireotide (n=71), or phosphate-buffered sal...